CASI Pharmaceuticals, Inc. (CASIF)
0.1288
-0.01
(-7.20%)
USD |
OTCM |
Aug 25, 16:00
CASI Pharmaceuticals Enterprise Value : 24.50M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 24.50M |
| August 24, 2026 | 24.71M |
| August 21, 2026 | 24.50M |
| August 20, 2026 | 24.50M |
| August 19, 2026 | 24.50M |
| August 18, 2026 | 24.72M |
| August 17, 2026 | 24.90M |
| August 14, 2026 | 24.90M |
| August 13, 2026 | 24.85M |
| August 12, 2026 | 24.57M |
| August 11, 2026 | 24.50M |
| August 10, 2026 | 24.32M |
| August 07, 2026 | 24.50M |
| August 06, 2026 | 24.50M |
| August 05, 2026 | 24.50M |
| August 04, 2026 | 24.50M |
| August 03, 2026 | 24.51M |
| July 31, 2026 | 24.50M |
| July 30, 2026 | 24.50M |
| July 29, 2026 | 24.71M |
| July 28, 2026 | 24.71M |
| July 27, 2026 | 24.50M |
| July 24, 2026 | 24.50M |
| July 23, 2026 | 24.50M |
| July 22, 2026 | 24.50M |
| Date | Value |
|---|---|
| July 21, 2026 | 24.63M |
| July 20, 2026 | 24.63M |
| July 17, 2026 | 25.27M |
| July 16, 2026 | 25.00M |
| July 15, 2026 | 24.73M |
| July 14, 2026 | 24.83M |
| July 13, 2026 | 25.84M |
| July 10, 2026 | 24.84M |
| July 09, 2026 | 24.83M |
| July 08, 2026 | 24.56M |
| July 07, 2026 | 24.56M |
| July 06, 2026 | 25.96M |
| July 02, 2026 | 24.87M |
| July 01, 2026 | 26.79M |
| June 30, 2026 | 25.35M |
| June 29, 2026 | 24.38M |
| June 26, 2026 | 24.53M |
| June 25, 2026 | 24.53M |
| June 24, 2026 | 24.23M |
| June 23, 2026 | 25.48M |
| June 22, 2026 | 24.94M |
| June 18, 2026 | 25.45M |
| June 17, 2026 | 24.81M |
| June 16, 2026 | 25.35M |
| June 15, 2026 | 24.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sinovac Biotech Ltd. | -210.46M |
| CanSino Biologics, Inc. | 830.34M |
| Shanghai Junshi Biosciences Co., Ltd. | 3.669B |
| Ascletis Pharma, Inc. | 1.194B |
| CStone Pharmaceuticals Co. Ltd. | 804.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.04M |
| Revenue (Quarterly) | 7.222M |
| Total Expenses (Quarterly) | 20.26M |
| EPS Diluted (Quarterly) | -0.6345 |
| Gross Profit Margin (Quarterly) | 51.14% |
| Profit Margin (Quarterly) | -180.6% |
| Earnings Yield | -2.23K% |
| Normalized Earnings Yield | -2221.27 |